A New Model For A New Era Of Psychedelic Therapy
Source: Life Science Leader
By Ben Comer, Chief Editor, Life Science Leader
By 2031, the Multidisciplinary Association for Psychedelic Studies, or MAPS, aims to have treated 1 million post-traumatic stress disorder (PTSD) patients with 3,4-methylenedioxymethamphetamine (MDMA), a psychoactive drug also known by the street names Ecstasy or Molly. Designated by the FDA as a Breakthrough Therapy in 2017 and currently undergoing Phase 3 trials in the U.S., Canada, and Israel, following the completion of an initial Phase 3 study in 2021, MDMA is the closest drug to FDA approval amid a rapidly expanding field of psychedelic medicines.
VIEW THE MAGAZINE ARTICLE! Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X
Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.
Subscribe to Life Science Leader X
Subscribe to Life Science Leader